Full Press Release Details
Creative Medical Technology Holdings
Reports completion and submission of Clinical Trial Data on
CaverStem Procedure for Drug Resistant Erectile Dysfunction Patients
Patients Who Underwent Patented Penile
Regenerative Procedure Using Their Own Bone Marrow
Concentrate will be Described in Peer Reviewed Paper
Phoenix, AZ September 4, 2019 Creative Medical Technology Holdings
(OTC-CELZ) reported today completion of data analysis and submission of a research paper describing a total of 140 patients
treated with the CaverStem procedure. The patients suffered from erectile dysfunction for whom standard drug interventions
such as Cialis, Levitra, and Viagra (PDE-5) were ineffective.
The data analysis demonstrated that primary end-point of the
"It is very exciting to see the patented cell based intervention
that we first described in peer reviewed literature in our 2013 publication1
has now grown to become a commercialized procedure, available through qualified physicians, after completing a clinical trial with
independent monitoring and oversight for safety and efficacy," said Amit Patel, MD, MS, Board Member of the Company.
In the submitted paper, a total of 40 patients were treated
in the primary trial and 100 in the clinical registry. This signifies one of the largest clinical studies of a non-drug
treatment for erectile dysfunction.
"The current data is derived from cells that are extracted
from the same patient that they are to be used on, and that the cells are not chemically or biologically manipulated. The devices
used for extraction and concentration of the cells are FDA cleared. This approach is completely different from unethical and potentially
dangerous approaches other groups are using including non-matched stem cells or fat derived stem cells using "home-made"
isolation protocols."
"Since founding the company and acquisition of the technology,
through patent prosecution to engaging in the clinical trials and now in the treatment of patients in multiple locations, we have
maintained an ongoing positive outlook for our CaverStem technology. The results which will be published in a peer-reviewed
journal as well as reflected on clinicaltrials.gov substantiate our long term belief in the potential safety and efficacy of our
technology," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings, Inc. "We are glad
to be offering this breakthrough treatment to patients with erectile dysfunction who currently have no other options as part of
the ongoing clinical registry."
To learn more, please visit www.caverstem.com
About Erectile Dysfunction
Erectile dysfunction (ED) is characterized by the lack of ability to achieve and maintain penile erection for intercourse.
Methods used to quantify ED include the Erectile Function Visual Analog Scale (EF-VAS) and the International Index of Erectile
Function (IIEF-5), however clinically it is primarily diagnosed based on symptomology. In our aging society, ED is becoming
an increasing problem. According to one study 39% of men at age 40 experience symptoms of ED, whereas by age 70 the incidence rises
to 67%. In this latter age group, it is believed that 50-85% of ED cases are associated with hypertension, diabetes, cardiovascular
disease and dyslipidemia. Overall, it is estimated that 10-30 million Americans suffer from this condition.
____________________________
Ichim et al. Intracavernous administration of bone marrow mononuclear cells: a new method of treating erectile dysfunction? J Transl
Med. 2013; 11: 139. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718667/
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage
biotechnology company specializing in stem cell technology in the fields of urology, neurology and orthopedics and trades on the
OTC under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com.
Forward Looking Statements
OTC Markets has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited
to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc.
Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual
results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by
Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website
Timothy Warbington, CEO